Beta Drugs Complete Financial Statements
In FY2026, Beta Drugs (BETA) reported revenue ₹97 Cr, net profit ₹9 Cr and EPS ₹8.93, with a net profit margin of 9.3% and ROE of 3.7%. Full financial statements from FY2018 to FY2026 (9 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Examine BETA quarterly trends for recent quarterly revenue, profit and EPS trends.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
BETA Revenue, Net Profit & EBITDA — Year-on-Year Growth
BETA YoY (Mar 2025 vs Mar 2026) — revenue -1.0%, EBITDA +10.5%, expenses -3.8%. For live price, earnings ratios and company overview, see BETA share price screener.
BETA Income Statement — Revenue, EBITDA & Net Profit
Beta Drugs revenue ₹97 Cr, EBITDA ₹21 Cr, net profit ₹9 Cr, EPS ₹8.93 (2026) — net profit margin 9.3%. Analyse BETA institutional holdings to track promoter, FII and institutional holdings.
| Particulars | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 97 | 127 | 106 | 98 | 103 | 90 | 89 |
| Expenses | 76 | 98 | 82 | 79 | 81 | 70 | 72 |
| EBITDA | 21 | 29 | 24 | 19 | 23 | 19 | 17 |
| Operating Profit Margin % | 19.00% | 22.00% | 21.00% | 16.00% | 20.00% | 19.00% | 18.00% |
| Depreciation | 5 | 4 | 4 | 4 | 4 | 4 | 3 |
| Interest | 4 | 3 | 4 | 3 | 3 | 4 | 2 |
| Profit Before Tax | 12 | 22 | 16 | 12 | 16 | 11 | 12 |
| Tax | 3 | 6 | 4 | 3 | 4 | 2 | 3 |
| Net Profit | 9 | 17 | 12 | 9 | 12 | 9 | 9 |
| Earnings Per Share (₹) | 8.93 | 14.78 | 12.10 | 9.40 | 11.59 | 8.40 | 9.31 |
BETA Balance Sheet — Assets, Liabilities & Shareholders' Equity
BETA total assets ₹496 Cr, total equity ₹245 Cr, total liabilities ₹ Cr (2026) — ROE 3.7%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Total Assets | 496 | 436 | 254 | 198 | 158 | 118 | 107 | 83 | 50 |
| Current Assets | 335 | 331 | 178 | 128 | 97 | 68 | 56 | 43 | 32 |
| Fixed Assets | 125 | 89 | 65 | 63 | 55 | 40 | 44 | 18 | 13 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 15 | 1 |
| Investments | 75 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 347 | 190 | 136 | 103 | 75 | 63 | 50 | 35 |
| LIABILITIES | |||||||||
| Total Liabilities | |||||||||
| Current Liabilities | 143 | 136 | 12 | 13 | 17 | 16 | 13 | 9 | 3 |
| Non-Current Liabilities | |||||||||
| SHAREHOLDERS' EQUITY | |||||||||
| Total Equity | 245 | 197 | 157 | 123 | 92 | 69 | 57 | 41 | 33 |
| Share Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 9 | 9 |
| Reserves & Surplus | 235 | 187 | 148 | 113 | 83 | 59 | 48 | 32 | 24 |
BETA Cash Flow Statement — Operating, Investing & Financing
Beta Drugs operating cash flow ₹36 Cr, investing ₹-36 Cr, financing ₹118 Cr, net cash flow ₹118 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | 36 | 31 | 23 | 30 | 19 | 8 | 0 | 17 |
| Investing Activities | -36 | -14 | -19 | -22 | -6 | -15 | -21 | -11 |
| Financing Activities | 118 | -8 | -3 | -1 | -8 | 9 | 12 | 5 |
| Net Cash Flow | 118 | 10 | 2 | 7 | 5 | 2 | -9 | 12 |